Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial

Clicks: 1
ID: 325231
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #182 of 197 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Ultra-low dose rituximab is an effective treatment in rheumatoid arthritis (RA). Subcutaneous (SC) administration may further facilitate rituximab treatment, reduce infection risk, and reduce costs. This study aimed to assess non-inferiority of SC versus intravenous (IV) rituximab regarding pharmacokinetic and -dynamic (PKPD) outcomes. METHODS: In this randomised, open-label, non-inferiority study, RA patients with stable low disease activity on ultra-low dose rituximab (500 mg or 200 mg every 6 months) were 1:1 randomised to receive rituximab 336 mg SC or 200 mg IV, stratified by previous rituximab dose. Primary outcome was non-inferiority of SC to IV rituximab, based on the estimated rituximab serum concentration area under the curve during the first 6 months (AUC0-6 months), with a non-inferiority margin of 0.8. AUCs were estimated using PK modelling. Secondary outcomes included change in DAS28-CRP compared to a NI-margin of 0.6. RESULTS: Thirty-five patients were randomised (17 IV, 18 SC). The geometric mean ratio for AUC0-6m was 0.99 (90%-CI 0.82 to 1.20), with minimal bias (mean predication error: IV 13.1 (1.86%); SC -3.40 (-0.47%)) but moderate random prediction error (root mean square error: IV 140 (19.8%); SC 142 (19.5%)) for the AUC estimates. Mean change in DAS28-CRP was non-inferior for SC rituximab (-0.39, 95%-CI -0.77 to -0.004). CONCLUSION: Our data suggest non-inferior pharmacokinetics for SC rituximab; however, this cannot be definitively concluded due to uncertainty of the AUC estimates. Nevertheless, based on PK/PD parameters, ultra-low dose SC rituximab could be an alternative for ultra-low dose IV rituximab.
Reference Key
openalex_W7203676107 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors P. Bovens, Céleste J T van der Togt, Nathan den Broeder, Lise M Verhoef, Aatke van der Maas, W Hobo, Karien Bloem, Rob ter Heine, Bart J. F. van den Bemt, Alfons A den Broeder
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag420
URL
https://doi.org/10.1093/rheumatology/keag420
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.